Biotechnology · Grasonville, Maryland, United States
$1.55
+3.33% (+$0.05)2026-08-24
Net Income-$8.6M
EPS$-0.46
Market Cap$70.2M
Price Performance
Historical data including institutional events
Company Profile
P
Paul Romness
CEO & Executive Director
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
